Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Lee Jackson | Nov 20, 2014 at 8:55 AM EST

4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential

A new report from the biotech team at Stifel focuses on catalysts from companies that are presenting at the firm's…

Chris Lange | Nov 19, 2014 at 1:50 PM EST

Is Orexigen Really Worth Over 50% More?

Merrill Lynch released an analyst report for Orexigen Therapeutics that sees more than 50% upside for the company.

Paul Ausick | Nov 18, 2014 at 1:25 PM EST

The Devastating Cost of Alzheimer’s Care

Providing care for a parent or loved one with Alzheimer's disease or other dementia costs $20,000 or more for 42%…

Chris Lange | Nov 17, 2014 at 1:55 PM EST

Is This the Sunesis Resurrection?

On Monday, Sunesis made an announcement that it would be making a presentation regarding its drug candidates vosaroxin and cytarabine.

Paul Ausick | Nov 17, 2014 at 10:05 AM EST

Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out

Botox maker Allergan has entered a definitive agreement to be acquired by Actavis, despite higher offer from Valeant Pharmaceuticals.

Chris Lange | Nov 17, 2014 at 9:45 AM EST

Juno Therapeutics Files for IPO

Juno Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.

Chris Lange | Nov 14, 2014 at 11:35 AM EST

What Licensing Imetelstat Will Mean for Geron

Geron hasannounced that it entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize…

Paul Ausick | Nov 13, 2014 at 1:15 PM EST

ReWalk Earnings Shine Spotlight on Robotics

ReWalk Robotics reported quarterly earnings Thursday morning for the first time since the company's initial public offering in mid-September.

Lee Jackson | Nov 13, 2014 at 9:15 AM EST

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

A new research report from the analysts at UBS focuses on four companies that stand to benefit from rising demand…

Chris Lange | Nov 12, 2014 at 2:10 PM EST

Ebola Stock Short Interest Surprise

Some Ebola-related stocks had been heavily shorted as they were considered by many investors as the next would-be stock bubble…

Jon C. Ogg | Nov 12, 2014 at 1:35 PM EST

Gilead Sees Large Insider Stock Sale Into Debt Offering

A Gilead Sciences bond offering and a key insider stock sale netting over $14 million should be considered by investors.

Chris Lange | Nov 12, 2014 at 8:40 AM EST

Biotech Short Interest Becomes Stock Specific (Updated)

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.

Lee Jackson | Nov 11, 2014 at 9:10 AM EST

New Cancer Detection Technique Has Enormous Potential for Life Science Stocks

A new report from Cowen makes the case that a blood test that detects evidence of cancer in the circulation…

Jon C. Ogg | Nov 10, 2014 at 8:15 AM EST

The Shame and Lessons of a Dendreon Bankruptcy

Dendreon has committed the ultimate sin by filing for bankruptcy protection.

Paul Ausick | Nov 7, 2014 at 7:45 AM EST

Humana Earnings Hit by High Drug Costs; Guidance Won’t Cheer Investors Either

Humana reported disappointing third-quarter 2014 results before markets opened Friday morning.

1 … 275 276 277 278 279 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential

Is Orexigen Really Worth Over 50% More?

The Devastating Cost of Alzheimer’s Care

Is This the Sunesis Resurrection?

Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out

Juno Therapeutics Files for IPO

What Licensing Imetelstat Will Mean for Geron

ReWalk Earnings Shine Spotlight on Robotics

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

Ebola Stock Short Interest Surprise

Gilead Sees Large Insider Stock Sale Into Debt Offering

Biotech Short Interest Becomes Stock Specific (Updated)

New Cancer Detection Technique Has Enormous Potential for Life Science Stocks

The Shame and Lessons of a Dendreon Bankruptcy

Humana Earnings Hit by High Drug Costs; Guidance Won’t Cheer Investors Either

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Ben Carlson Calls Out the Goldman Survey That Says 40% of $500K Earners Live Paycheck-to-Paycheck. The Definition Is the Problem.

Andrew Sather Says Companies Are Getting “Creative” With Stock Dilution. Here’s How to Spot When It’s Quietly Costing You

AMD Sinks 6% Despite a Holding Pattern in Intel and NVIDIA: The Selective AI Chip Trade Is Here

Ben Carlson Calls Out the Goldman Survey That Says 40% of $500K Earners Live Paycheck-to-Paycheck. The Definition Is the Problem.

I Have $7.5 Million in a Traditional IRA at 60 — How Aggressively Should I Do Roth Conversions?

Ben Carlson Calls Out the Goldman Survey That Says 40% of $500K Earners Live Paycheck-to-Paycheck. The Definition Is the Problem.

Andrew Sather Says Companies Are Getting “Creative” With Stock Dilution. Here’s How to Spot When It’s Quietly Costing You

Health and Healthcare Articles

All Health and Healthcare Articles

4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential

Is Orexigen Really Worth Over 50% More?

The Devastating Cost of Alzheimer’s Care

Is This the Sunesis Resurrection?

Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out

Juno Therapeutics Files for IPO

What Licensing Imetelstat Will Mean for Geron

ReWalk Earnings Shine Spotlight on Robotics

4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic

Ebola Stock Short Interest Surprise

Gilead Sees Large Insider Stock Sale Into Debt Offering

Biotech Short Interest Becomes Stock Specific (Updated)

New Cancer Detection Technique Has Enormous Potential for Life Science Stocks

The Shame and Lessons of a Dendreon Bankruptcy

Humana Earnings Hit by High Drug Costs; Guidance Won’t Cheer Investors Either

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Ben Carlson Calls Out the Goldman Survey That Says 40% of $500K Earners Live Paycheck-to-Paycheck. The Definition Is the Problem.

Andrew Sather Says Companies Are Getting “Creative” With Stock Dilution. Here’s How to Spot When It’s Quietly Costing You

AMD Sinks 6% Despite a Holding Pattern in Intel and NVIDIA: The Selective AI Chip Trade Is Here

Featured Reads

Ben Carlson Calls Out the Goldman Survey That Says 40% of $500K Earners Live Paycheck-to-Paycheck. The Definition Is the Problem.

I Have $7.5 Million in a Traditional IRA at 60 — How Aggressively Should I Do Roth Conversions?